Evidence map›Paper›PMID 40877486›Full record

ArticleScientific reports2025

UPP1 is a dual biomarker of prognosis and immune microenvironment in IDH wild-type glioblastoma.

Kecheng Qian, Zhaoxing Jia, Qian Cai, Tianxiang Jiang, Lin Gan, Jinding Yang, Xiaokai Cen, Yuhui Zhao, Zhong Di, Congcong Ma and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kecheng Qian *The Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Zhaoxing Jia *The Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Qian Cai *The Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Tianxiang Jiang *The Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Lin GanThe Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Jinding YangThe Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Xiaokai CenThe Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Yuhui ZhaoThe Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Zhong DiThe Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, Zhejiang, China.
Congcong MaThe Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, Zhejiang, China. macongcong19940307@163.com.
Xianming LinThe Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China. linxianming1966@163.com.

Funding

National Natural Science Foundation of China 82474626Science and Technology Department of the National Administration of Traditional Chinese Medicine and the Zhejiang Provincial Administration of Traditional Chinese Medicine GZY-ZJ-KJ-24021Zhejiang University of Traditional Chinese Medicine 2024 Student Research Fund Funded Project A multi-functional multi-site rat fixator
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor. Current therapies (temozolomide/radiotherapy) often encounter resistance, necessitating novel molecular targets. Bioinformatics analysis was performed for the data obtained from TCGA, COSMIC, cbioPortal, and MethSurv databases. Tools such as GO, KEGG, GSEA, ROC, and protein-protein interactions (PPI) were employed to investigate the role that UPP1 has on GBM. The effects of UPP1 were further validated using RT-PCR and Western blotting(WB). UPP1 overexpression correlated with poor survival (P < 0.05) and immunosuppression, showing positive associations with immune infiltrates (Tregs, DCs, Th1/Th17 cells) and inflammation-related pathway activation. Silencing UPP1 suppressed proliferation (P < 0.001) in glioma cells. Several DNA methylation patterns of UPP1(8 CpG sites, e.g., cg07703017) were identified as having significant prognostic value. UPP1 drives immunosuppression and serves as a dual biomarker: expression levels stratify prognosis, while methylation profiles offer therapeutic insights. Its immunometabolic regulation positions UPP1 as a promising target for GBM precision therapy.

Indexed as

Biomarkers, TumorBrain NeoplasmsGlioblastomaIsocitrate DehydrogenaseTumor MicroenvironmentCell Line, TumorDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorIDH1 protein, humanIsocitrate DehydrogenaseBiomarkerGliomaImmune infiltrationUPP1

Identifiers

PMID40877486
PMCPMC12394549

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.